These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19663674)

  • 1. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.
    Arnett DK; Claas SA
    Pharmacogenomics; 2009 Aug; 10(8):1295-307. PubMed ID: 19663674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of antihypertensive drug responses.
    Schwartz GL; Turner ST
    Am J Pharmacogenomics; 2004; 4(3):151-60. PubMed ID: 15174896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive pharmacogenetics: getting the right drug into the right patient.
    Turner ST; Schwartz GL; Chapman AB; Hall WD; Boerwinkle E
    J Hypertens; 2001 Jan; 19(1):1-11. PubMed ID: 11204288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the pharmacogenetics of treating hypertension.
    Fontana V; Luizon MR; Sandrim VC
    J Hum Hypertens; 2015 May; 29(5):283-91. PubMed ID: 25355012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in pharmacogenomics of drugs acting on hypertension.
    Trotta R; Donati MB; Iacoviello L
    Pharmacol Res; 2004 Apr; 49(4):351-6. PubMed ID: 15202514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of antihypertensive drugs: past, present and future.
    Johnson JA
    Pharmacogenomics; 2010 Apr; 11(4):487-91. PubMed ID: 20350127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?
    Arnett DK; Claas SA; Lynch AI
    Curr Opin Cardiol; 2009 Jul; 24(4):333-9. PubMed ID: 19509486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.
    Kurland L
    Minerva Med; 2003 Aug; 94(4):251-8. PubMed ID: 14605589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive pharmacogenetics.
    Nogueira JB
    Rev Port Cardiol; 2004 Dec; 23(12):1621-30. PubMed ID: 15732663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
    Hiltunen TP; Donner KM; Sarin AP; Saarela J; Ripatti S; Chapman AB; Gums JG; Gong Y; Cooper-DeHoff RM; Frau F; Glorioso V; Zaninello R; Salvi E; Glorioso N; Boerwinkle E; Turner ST; Johnson JA; Kontula KK
    J Am Heart Assoc; 2015 Jan; 4(1):e001521. PubMed ID: 25622599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic approaches to study the effects of antihypertensive drugs.
    Kamide K; Kawano Y; Rakugi H
    Hypertens Res; 2012 Aug; 35(8):796-9. PubMed ID: 22739423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of antihypertensive drug response.
    Kreutz R
    Curr Hypertens Rep; 2004 Feb; 6(1):15-20. PubMed ID: 14972084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics considerations in the control of hypertension.
    Lupoli S; Salvi E; Barcella M; Barlassina C
    Pharmacogenomics; 2015 Nov; 16(17):1951-64. PubMed ID: 26555875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.
    Lam YW; Shepherd AM
    Clin Pharmacokinet; 1990 Apr; 18(4):295-317. PubMed ID: 2182265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics and pharmacogenomics. Searching for individual antihypertensive therapy concepts].
    Brand E
    MMW Fortschr Med; 2003 May; 145(19):43-4. PubMed ID: 12813978
    [No Abstract]   [Full Text] [Related]  

  • 17. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment.
    Suonsyrjä T; Donner K; Hannila-Handelberg T; Fodstad H; Kontula K; Hiltunen TP
    Pharmacogenet Genomics; 2010 May; 20(5):342-5. PubMed ID: 20300048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension in African Populations: Review and Computational Insights.
    Mabhida SE; Mashatola L; Kaur M; Sharma JR; Apalata T; Muhamed B; Benjeddou M; Johnson R
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33917487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies.
    Loganathan L; Gopinath K; Sankaranarayanan VM; Kukreti R; Rajendran K; Lee JK; Muthusamy K
    Curr Drug Targets; 2020; 21(1):18-33. PubMed ID: 31393243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension.
    Rahman F; Muthaiah N; Kumaramanickavel G
    Indian J Pharmacol; 2021; 53(4):301-309. PubMed ID: 34414909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.